Why the study?
Data on off-label thrombopoietin receptor agonist use in refractory thrombocytopenia beyond current indications remain scarce, with potential risks such as thrombosis.
Does off-label use of TPO-RAs improve response rates in patients with refractory thrombocytopenia?
Comparison
Off-label thrombopoietin receptor agonist use across three etiology groups
Design
Single-center case series
Authors
Loading...
Off-label TPO-RA use in refractory thrombocytopenia warrants caution; leaves open questions on efficacy and thrombosis risk pending controlled data.
Does off-label use of TPO-RAs improve response rates in patients with refractory thrombocytopenia?
Off-label use of TPO-RAs appears effective and safe for managing refractory thrombocytopenia in myelodysplastic syndromes, post-transplantation, and lymphoproliferative diseases.
Capecchi et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: